COST-EFFECTIVENESS OF VEDOLIZUMAB COMPARED WITH USTEKINUMAB AS TREATMENT FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE IN THE UNITED STATES

被引：0

作者：

Zouraq, Azzabi, I ^{[1
]}

Wilson, M. ^{[2
]}

Hather, G. ^{[3
]}

Curtis, R. ^{[4
]}

Luo, M. ^{[5
]}

Khalid, J. M. ^{[4
]}

Minda, K. ^{[1
]}

机构：

[1] Takeda Pharmaceut Int AG, Zurich, Switzerland

[2] RTI Hlth Sci, Res Triangle Pk, NC USA

[3] Takeda Pharmaceut, Cambridge, MA USA

[4] Takeda Dev Ctr Europe Ltd, London, England

[5] Takeda Pharmaceut Inc, Deerfield, IL USA

来源：

VALUE IN HEALTH | 2017年 / 20卷 / 05期

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PGI20

引用

页码：A183 / A183

页数：1

共 50 条

[1] Cost-Effectiveness of Vedolizumab Compared With Conventional Therapy and Biologics for Treatment of Moderately to Severely Active Ulcerative Colitis in the United States
Wilson, Michele
Mody, Reema
Ursan, Iulia
Carr, Sean
GASTROENTEROLOGY, 2015, 148 (04) : S198 - S199
[2] COST-EFFECTIVENESS ANALYSIS OF USTEKINUMAB VERSUS ADALIMUMAB, INFLIXIMAB AND VEDOLIZUMAB FOR THE TREATMENT OF PATIENTS WITH MODERATELY TO SEVERE ACTIVE CROHN'S DISEASE FOR TURKEY
Arhan, M.
Tezel, H. A.
Toruner, M.
Bilaloglu, B.
Koral, S.
Ozer, E.
VALUE IN HEALTH, 2018, 21 : S145 - S145
[3] THE COST-EFFECTIVENESS OF USTEKINUMAB IN MODERATE TO SEVERELY ACTIVE CROHN'S DISEASE IN SWEDEN
Hansson-Hedblom, A.
Almond, C.
Borgstrom, F.
Sly, I
Enkusson, D.
Buchholt, Troelsgaard A.
Karlsson, L.
VALUE IN HEALTH, 2017, 20 (09) : A634 - A634
[4] COST-EFFECTIVENESS OF VEDOLIZUMAB COMPARED WITH CONVENTIONAL THERAPY FOR TREATMENT OF MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS IN THE UNITED KINGDOM
Wilson, M.
Kerrigan, M.
Smyth, M.
Chevrou-Severac, H.
Bergman, A.
Selby, R.
GUT, 2016, 65 : A260 - A260
[5] COST-EFFECTIVENESS OF VEDOLIZUMAB COMPARED WITH INFLIXIMAB, ADALIMUMAB, AND GOLIMUMAB FOR TREATMENT OF MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS IN THE UNITED KINGDOM
Wilson, M.
Kerrigan, M.
Smyth, M.
Chevrou-Severac, H.
Bergman, A.
Selby, R.
GUT, 2016, 65 : A260 - A261
[6] COST-EFFECTIVENESS OF VEDOLIZUMAB COMPARED WITH CONVENTIONAL THERAPY IN PATIENTS WITH CROHN'S DISEASE IN THE UNITED KINGDOM (UK)
Robson, R. E.
Vanoli, A.
Tolley, K.
VALUE IN HEALTH, 2018, 21 : S455 - S456
[7] COST-EFFECTIVENESS OF VEDOLIZUMAB FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS IN RUSSIA
Pyadushkina, E.
Derkach, E., V
VALUE IN HEALTH, 2017, 20 (09) : A635 - A635
[8] COST-EFFECTIVENESS OF VEDOLIZUMAB VERSUS USTEKINUMAB IN UNITED KINGDOM CROHN'S DISEASE PATIENTS WHO PREVIOUSLY FAILED TNF INHIBITOR THERAPY
Wilson, M.
Lucas, A.
VALUE IN HEALTH, 2018, 21 : S145 - S145
[9] A MARKOV MODEL EVALUATING THE COST-EFFECTIVENESS OF USTEKINUMAB COMPARED TO VEDOLIZUMAB FOR PATIENT'S WITH CROHN'S DISEASE AS THIRD-LINE THERAPY
Schneider, Yecheskel
Saumoy, Monica
Cohen-Mekelburg, Shirley A.
Gold, Stephanie
Scherl, Ellen
Steinlauf, Adam F.
GASTROENTEROLOGY, 2017, 152 (05) : S589 - S589
[10] REAL-WORLD EFFECTIVENESS OF USTEKINUMAB IN BIO-NAIVE PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE IN CANADA
Bessissow, Talat
Narula, Neeraj
Ma, Christopher
In, Tracy S.
Eberg, Maria
Karra, Kinda
Belgnaoui, Mehdi
Jairath, Vipul
GASTROENTEROLOGY, 2022, 162 (07) : S811 - S811

← 1 2 3 4 5 →